on Hardman & Co Research (isin : GB00BYYW9G87)
Hardman & Co Research on Shield Therapeutics (STX): Focusing on Successful Execution
Shield Therapeutics, a commercial-stage pharmaceutical company, is making strides in addressing iron deficiency (ID) in patients with its specialty product, ACCRUFeR®. Since its US launch in July 2021, Shield and its partner Viatris have worked to increase physician awareness of ACCRUFeR®'s distinct characteristics as an oral medication for ID, aiming to boost sales.
The first half of 2024 has seen promising sales figures while maintaining strict cost control. Management remains confident that the combination of its substantial cash reserves and anticipated growth will sustain the company through to cashflow-breakeven by the second half of 2025.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Hardman & Co Research news